Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02503709 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions

DRUG: CDK Inhibitor AT7519
OTHER: Laboratory Biomarker Analysis
DRUG: Onalespib
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)